Your browser doesn't support javascript.
loading
Clinical characteristics and long-term follow-up outcomes of myelin oligodendrocyte glycoprotein antibody-associated disease in Han Chinese participants.
Zeng, Wei; Yu, Lu; Wu, Jiarui; Wang, Fang; Liu, Xudong; Ren, Shuqun; Zhang, Daxue; Lian, Baorong; Hu, Minghua; Cao, Liming.
Afiliação
  • Zeng W; Department of Neurology, Liuzhou People's Hospital, Liuzhou, China.
  • Yu L; Department of Neurology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Wu J; The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, China.
  • Wang F; Department of Neurology, Liuzhou People's Hospital, Liuzhou, China.
  • Liu X; Department of Neurology, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Ren S; School of Nursing, Guangxi University of Chinese Medicine, Nanning, China.
  • Zhang D; School of Nursing, Anhui Medical University, Hefei, China.
  • Lian B; Shantou University Medical College, Shantou University, Shantou, China.
  • Hu M; Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China.
  • Cao L; Department of Neurology, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Medicine (Baltimore) ; 102(40): e35391, 2023 Oct 06.
Article em En | MEDLINE | ID: mdl-37800805
ABSTRACT
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated inflammatory demyelinating disease of the central nervous system. This study aimed to delineate the clinical manifestations, imaging features, and long-term outcomes in Chinese patients with MOGAD and analyze the recurrence-associated factors. The phenotypic and neuroimaging characteristics of 15 Han Chinese patients with MOGAD were retrospectively analyzed. Demyelinating attacks, MOG antibodies in the cerebrospinal fluid/serum, response to immunotherapy, follow-up outcomes, and recurrence-associated factors were recorded. The median age at disease onset was 34 years (range, 4-65 years). The most common initial presentations included vision loss (10/15, 66.7%) and seizures (5/15, 33.3%). Serum MOG-Ab titers in 14/15 cases were higher than those in the cerebrospinal fluid and were detected in 3/6 relapsed patients. Brain magnetic resonance imaging during acute attacks showed lesions in 10/15 patients (66.7%), mostly in the cortex/subcortical white matter (5/15, 33.3%). Recurrence occurred in 6/15 patients (40.0%); in 4 patients, recurrence occurred shortly after immunotherapy discontinuation. Residual neurological deficits were present in 5/15 patients (33.3%), including visual impairment, incapacitation, cognitive impairment, and speech reduction. Optic neuritis was the most common clinical manifestation of MOGAD. magnetic resonance imaging findings were heterogeneous and the cerebral cortex/subcortical white matter was the most susceptible brain region. Although patients in the acute phase responded well to methylprednisolone pulse therapy, the long-term recurrence rate was high. Consistently detected serum MOG antibodies and inappropriate maintenance immunotherapy may be associated with recurrence, and residual neurological deficits should not be ignored.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Encéfalo / Doenças Desmielinizantes / População do Leste Asiático Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Child / Child, preschool / Humans / Middle aged Idioma: En Revista: Medicine (Baltimore) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Encéfalo / Doenças Desmielinizantes / População do Leste Asiático Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Child / Child, preschool / Humans / Middle aged Idioma: En Revista: Medicine (Baltimore) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China